ClinicaliQ Trial Snapshot
- A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) — Active Not Recruiting • Phase III • Mental Health / Psychiatry • NCT06809595.
- MM120 was tested against placebo for anxiety disorder in a large, rigorous trial with long-term follow-up.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Panorama Conditions: Generalized Anxiety Disorder Interventions: Placebo, MM120 (LSD D-Tartrate) Lead Sponsor: Definium Therapeutics US, Inc. Planned Enrollment: 250 participants